Compare Sana Biotechnology Inc (SANA) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Suncor Energy Inc. — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Suncor Energy Inc. trades at $63.28 (market cap $74.07B). The key difference: Suncor Energy Inc. is far larger — about 65.5× Sana Biotechnology Inc's market cap, and Suncor Energy Inc. pays a 2.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SU | |
|---|---|---|
Market Cap | $1.13B | $74.07B |
Sector | Health | Energy |
52-Week High | $5.92 | $69.73 |
52-Week Low | $2.68 | $38.17 |
Enterprise Value | $1.05B | $80.75B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Suncor Energy (SU) trades at $63.82, up 1.74% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.79, a net income margin of 14.7%, and a robust ROE of 19.25%. Recent Q2 2026 earnings beat estimates, and the company has declared consistent dividends. Leadership transition plans are in place, with Peter Zebedee set to become CEO in 2027.
The outlook is positive, supported by strong cash flow, shareholder returns, and favorable analyst sentiment. Key risks include commodity price volatility and operational challenges. With 74% of analysts rating it a buy and no sell ratings, the stock presents a compelling opportunity for value and income investors, though macroeconomic factors remain a watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
